- Home
- WRBY vs IMCR Comparison
WRBY vs IMCR Comparison
Compare WRBY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- IMCR
- Stock Information
- Founded
- WRBY 2010
- IMCR 2008
- Country
- WRBY United States
- IMCR United Kingdom
- Employees
- WRBY N/A
- IMCR N/A
- Industry
- WRBY Ophthalmic Goods
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WRBY Health Care
- IMCR Health Care
- Exchange
- WRBY Nasdaq
- IMCR Nasdaq
- Market Cap
- WRBY 2.7B
- IMCR 1.8B
- IPO Year
- WRBY 2021
- IMCR 2021
- Fundamental
- Price
- WRBY $28.34
- IMCR $33.42
- Analyst Decision
- WRBY Buy
- IMCR Buy
- Analyst Count
- WRBY 16
- IMCR 9
- Target Price
- WRBY $24.40
- IMCR $57.00
- AVG Volume (30 Days)
- WRBY 1.4M
- IMCR 280.0K
- Earning Date
- WRBY 11-06-2025
- IMCR 11-05-2025
- Dividend Yield
- WRBY N/A
- IMCR N/A
- EPS Growth
- WRBY N/A
- IMCR N/A
- EPS
- WRBY N/A
- IMCR N/A
- Revenue
- WRBY $821,347,000.00
- IMCR $356,145,000.00
- Revenue This Year
- WRBY $17.16
- IMCR $29.67
- Revenue Next Year
- WRBY $14.64
- IMCR $11.12
- P/E Ratio
- WRBY N/A
- IMCR N/A
- Revenue Growth
- WRBY 14.09
- IMCR 26.78
- 52 Week Low
- WRBY $13.63
- IMCR $23.15
- 52 Week High
- WRBY $29.73
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- WRBY 64.75
- IMCR 44.21
- Support Level
- WRBY $26.18
- IMCR $35.33
- Resistance Level
- WRBY $27.36
- IMCR $36.76
- Average True Range (ATR)
- WRBY 0.79
- IMCR 1.57
- MACD
- WRBY 0.04
- IMCR -0.20
- Stochastic Oscillator
- WRBY 98.70
- IMCR 24.65
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.